Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies

Harnessing the power of the immune system to recognize and eliminate cancer cells is a longtime exploration. In the past decade, monoclonal antibody (mAb)-based immune checkpoint blockade (ICB) and chimeric antigen receptor T (CAR-T) cell therapy have proven to be safe and effective in hematologic m...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hao, Kaur, Gurbakhash, Sankin, Alexander I., Chen, Fuxiang, Guan, Fangxia, Zang, Xingxing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558778/
https://www.ncbi.nlm.nih.gov/pubmed/31186046
http://dx.doi.org/10.1186/s13045-019-0746-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558778/
https://www.ncbi.nlm.nih.gov/pubmed/31186046
http://dx.doi.org/10.1186/s13045-019-0746-1

Ejemplares similares